[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"masld---metabolic-dysfunction-associated-steatotic-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:masld---metabolic-dysfunction-associated-steatotic-liver-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,44,75,102,125,149,179,211,253,277,298,323,345,374,405,427,451,477,498,525,558,580,617],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622961","duodenal-pulsendo-for-suboptimally-controlled-type-ii-diabetes-mellitus-and-steatotic-liver-disease-100622961",false,"NCT07390422","Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease","Duodenal Recellularization Via Electroporation Therapy for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease (DRESS-1 Study)","DRESS-1","Inclusion Criteria:\n\n* Duration of T2DM \\\u003C 10 years\n* BMI 18.5-40kg\u002Fm2\n* Failure to achieve adequate HbA1c reduction (7.5 - 11%) after at least 3 months stable dosage of oral glucose lowering drugs\n\nExclusion Criteria:\n\n* Previous treatment with pulsENDO or similar procedure\n* Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO\n* Type 1 DM, DM secondary to specific disease or having any history of ketoacidosis\n* Patients on insulin\n* Fasting C-peptide level \\\u003C0.5ug\u002FL\n* Any inflammatory disease of the gastrointestinal tract such as Crohn's disease\n* Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study\n* Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000\u002Fmicroliter or known coagulopathy\n* Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to study and\u002For there is a need or expected need to use during the study period\n* Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics)\n* Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month\n* Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder.\n* Patients with contra-indications to endoscopy\n* Patients with cirrhosis due to causes other than MASLD\n* Malignancy\n* Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)\n* Pregnant or breast feeding\n* ASA grade IV \\& V\n* Mental or psychiatric disorder; Drug or alcohol addiction\n* Other cases deemed by the examining physician as unsuitable for safe treatment\n* Refusal to participate","ALL","18 Years","70 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.",[28,29,30],"T2DM (Type 2 Diabetes Mellitus)","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Syndrome (MetS)","NOT_YET_RECRUITING","2026-06-20",{"date":34,"type":35},"2026-06-24","ACTUAL",{"date":37,"type":22},"2026-09-01",{"date":39,"type":22},"2033-08-30",{"name":41,"class":42},"Chinese University of Hong Kong","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100617006","assessment-of-gut-microbiota-derived-amino-acid-metabolite-production-in-patients-with-masld-100617006","NCT07313007","Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD","Evaluation of the Production of Amino Acid-Derived Metabolites by the Gut Microbiota of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","MASLD-GUT","Inclusion Criteria:\n\n* For patients and healthy volunteers:\n\n  * Age between 18 and 80 years.\n  * Non-diabetic participant (fasting blood glucose \\\u003C 1.26 g\u002FL, or absence of insulin therapy or oral antidiabetic medication).\n  * Body mass index (BMI) between 18 and 30 kg\u002Fm².\n  * For women of childbearing potential, use of at least one recognized effective contraceptive method.\n  * Very regular bowel movements every 24 to 48 hours.\n  * Participant living within 100 km of the Lyon Sud Hospital Center (CHLS).\n  * Participant willing to participate in the study and providing written informed consent.\n  * Participant affiliated with the general French Social Security system or an equivalent scheme.\n* For patients:\n\n  * Presence of MASLD according to the definition of the European Association for the Study of the Liver (EASL), defined by hepatic steatosis on imaging performed within the previous year (abdominal ultrasound, abdominal CT scan, magnetic resonance imaging, or controlled attenuation parameter (CAP) measured by FibroScan) and at least one cardiometabolic criterion among: dyslipidemia, arterial hypertension, overweight (BMI ≥ 25 kg\u002Fm²), impaired glucose tolerance, or type 2 diabetes.\n  * No history of liver transplantation.\n  * No excessive alcohol consumption (less than 20 g\u002Fday for women and less than 30 g\u002Fday for men).\n  * Patient followed in the Endocrinology, Diabetes and Nutrition Department at Lyon Sud Hospital.\n\nExclusion Criteria:\n\n* For patients and healthy volunteers:\n\n  * Participant with active inflammatory, infectious, cardiovascular, or neoplastic disease.\n  * Participant with a history of colectomy, small bowel resection, or cholecystectomy.\n  * Participant who received antibiotics, prebiotics, or probiotics within the past 3 months.\n  * Participant using laxatives (more than 2 doses per day over the past 3 months).\n  * Participant with chronic constipation.\n  * Pregnant, parturient, or breastfeeding women.\n  * Participant deprived of liberty by judicial or administrative decision.\n  * Participant receiving psychiatric care.\n  * Participant institutionalized for reasons other than research.\n  * Adult participant under legal protection (guardianship or trusteeship).\n  * Participant who does not understand the French language and cannot provide informed consent.\n  * Participant already enrolled in a study presenting a conflict of interest with the present study.\n* For healthy volunteers\n\n  * Known liver disease\n  * No long-term drug medication except oral contraception for women.",true,"80 Years",{"count":55,"type":22},24,[25],"Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver disorders ranging from simple steatosis-a relatively benign and non-progressive condition-to metabolic dysfunction-associated steatohepatitis (MASH), characterized by hepatocellular inflammation. MASLD is now the leading cause of chronic liver disease worldwide, affecting approximately one in three adults, particularly those with obesity or type 2 diabetes.\n\nRecent studies have highlighted a strong interconnection between the gut microbiota, the liver, metabolism, and the immune system, collectively referred to as the gut-liver axis. Alterations in the gut microbiota are observed at all stages of MASLD, and several microbial metabolites-such as trimethylamine, bile acids, short-chain fatty acids, and ethanol-have been implicated in disease progression.\n\nEmerging evidence points to a role for gut-derived metabolites of tryptophan (Trp) and phenylalanine (Phe), including phenylacetic acid (PAA), 3-(4-hydroxyphenyl)-lactate (HPL), and phenyllactate (PL). These compounds have been associated with the severity of MASLD, particularly with hepatic steatosis and fibrosis. Elevated plasma levels of aromatic amino acids (AAAs), such as L-phenylalanine and L-tyrosine, are also correlated with increased hepatic fat content.\n\nA newly identified Phe-derived metabolite, N-acetyl-phenylalanine (NAPA), together with PAA, HPL, and PL, has been shown to correlate with hepatic steatosis. These metabolites can induce steatosis both in vitro and in vivo, acting through the disruption of endoplasmic reticulum-mitochondria interactions. They therefore represent potential new therapeutic targets.\n\nThese four metabolites of interest (NAPA, PAA, HPL, PL) can be produced both by gut bacteria and through endogenous human metabolism. Positive correlations between plasma NAPA concentrations and specific bacterial species have been observed, although the responsible taxa remain to be identified.\n\nHYPOTHESIS\n\nWe hypothesize that the gut microbiota of MASLD patients produces aromatic amino acid-derived metabolites, contributing to the elevated plasma concentrations observed in these patients\n\nTwo complementary strategies will be used : Human Microbiota Culture and Fecal Microbiota Transplantation",[29,59],"Metabolic Dysfunction-Associated Steatohepatitis (MASH)",[61,62,63,64],"MASLD","MASH","GUT MICROBIOTA","N-acétyl-phenylalanine (NAPA)","RECRUITING","2026-06-17",{"date":68,"type":35},"2026-06-22",{"date":70,"type":35},"2026-06-16",{"date":72,"type":22},"2027-01-16",{"name":74,"class":42},"Hospices Civils de Lyon",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":43},"100624654","evoo-and-metabolic-liver-health-in-masld-100624654","NCT07412444","EVOO and Metabolic Liver Health in MASLD","Evaluation of the Effects of Extra Virgin Olive Oil Consumption on Hepatic Steatosis Parameters and on Glucose and Lipid Metabolism in Subjects With MASLD.","EvoLiveR","Inclusion Criteria:\n\n* Subjects with 20 ≤ BMI \\\u003C 30;\n* Age range between 18 and 65 years, both sexes;\n* Diagnosis of hepatic steatosis, made on the basis of recognized criteria (FibroScan \\[CAP (controlled attenuation parameter) \\> 288 dB\u002Fm\\], FLI).\n\nExclusion Criteria:\n\n* Subjects with BMI \\\u003C 20 and BMI \\> 30.\n* Presence of any condition that may influence the occurrence of steatosis other than the conditions representing inclusion criteria.\n* Pregnancy or breastfeeding.\n* Severe medical conditions that may compromise participation in the trial.\n* Individuals following a special diet.","65 Years",{"count":85,"type":22},60,[25],"MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and other cardio-metabolic risk factors. Lifestyle modification, particularly through the Mediterranean Diet, is the first-line intervention, and extra virgin olive oil is a key component thanks to its monounsaturated fatty acids and bioactive compounds with anti-inflammatory and antioxidant effects.\n\nSeveral studies indicate that extra virgin olive oil supplementation, especially within a Mediterranean Diet pattern, reduces hepatic steatosis, improves inflammation, oxidative stress, and glucose and lipid profiles, and may promote weight loss and reduction of fat mass, also through potential effects on the gut microbiota. EFSA recognizes protective effects with a daily intake of at least 20 g of extra virgin olive oil, but it is still unclear whether this amount is optimal for individuals with MASLD, particularly those who are overweight or obese",[29,89],"Overweight",[61,89,91,92,93],"EVOO","Glucose Metabolism","Lipid Metabolism","2026-05-05",{"date":96,"type":35},"2026-05-06",{"date":96,"type":35},{"date":99,"type":22},"2028-05-06",{"name":101,"class":42},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100604011","phase-2-a-study-to-evaluate-the-use-of-resmetirom-in-participants-with-masld-and-hiv-100604011","NCT07143968","A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Resmetirom for the Treatment of Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD) in People Living With Human Immunodeficiency Virus (HIV)","Inclusion Criteria:\n\n1. Adults (≥18 years of age) with documented HIV.\n2. Documented diagnosis of MASLD established by imaging (ultrasound, CT scan or MRI) or vibration-controlled transient elastography (VCTE) or liver biopsy within 12 months before screening.\n3. Hepatic fat fraction ≥8% by MRI-PDFF.\n4. Liver stiffness by VCTE ≥8 kPa and CAP≥263 dB\u002Fm\n5. HIV-1 RNA \\\u003C200 copies\u002FmL for ≥6 months on antiretroviral therapy (ART) (must have screening HIV-1 RNA value and one clinical care value within 6 months prior to screening and up to the randomization that meet the criteria).\n6. Stable ART regimen for ≥3 months prior to screening and stable up to the randomization and no active plans to change ART while on study.\n7. Willingness to participate in the study.\n\nExclusion Criteria:\n\n1. History of significant alcohol consumption (defined as \\>2 drinks\u002Fday on average for men, \\>1 drinks\u002Fday on average for women) for at least 3 consecutive months (12 consecutive weeks) within 5 year before screening\n2. History of other acute or chronic liver disease, including, but not limited to autoimmune, primary biliary cholangitis, Wilson's disease, alpha 1 antitrypsin deficiency, hemochromatosis, hepatitis B virus (HBV), and ongoing or recent (within the past 3 years) hepatitis C RNA positivity.\n3. History of liver transplant.\n4. Liver biopsy or radiologic imaging consistent with the clinical presence of cirrhosis or portal hypertension at screening.\n5. Participants whose Visit 2 ALT, AST, or alkaline phosphatase (ALP) values exceed their Visit 1 values by more than 50%.\n6. Inability to undergo MRI testing\n7. Uncontrolled T2DM defined as glycated hemoglobin (HbA1c) \\>9.5% at screening.\n8. Any of the following laboratory values at screening:\n\n   1. ALT or AST \\>250 U\u002FL.\n   2. Total bilirubin (TBL) \\>1.5 mg\u002FdL and direct bilirubin \\> 0.5 mg\u002FdL (unless due to Gilbert's disease or atazanavir use, per the opinion of the site investigator).\n   3. Platelet count \\\u003C150,000\u002Fmm3.\n   4. Estimated glomerular filtration rate (e-GFR) \\\u003C60 mL\u002Fmin\u002F1.73m2 using the chronic kidney disease-epidemiology collaboration (CKD-EPI) equation\n   5. International normalized ratio (INR) \\>1.3.\n   6. Albumin \\\u003C 3.6 g\u002FdL\n9. Liver stiffness measurement (LSM) by VCTE \\> 20 kPa\n10. Further exclusion criteria apply",{"count":110,"type":22},120,[112],"PHASE2","The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV. This is a research study to test a drug that is already on the market with a population that was not included in the original clinical trials. Participants will be people over age 18 with HIV who are on antiretroviral therapy and have been diagnosed with MASLD.\n\nResearchers will compare resmetirom to placebo (a look-alike substance that contains no drug) to see if resmetirom decreases the amount of fat in the liver.\n\nParticipants will:\n\n* Complete 3 screening visits to determine eligibility.\n* Take resmetirom or placebo every day for 24 weeks if eligible.\n* Have 2 MRI scans to measure the amount of fat on the liver. One will be before treatment starts and one will be at the end of 24 weeks of treatment.\n* Attend 3 scheduled clinic visits while on treatment for bloodwork and safety assessments.\n* Participate in 3 phone calls while on treatment and one phone call 4 weeks after treatment is completed to check for safety and any health changes.",[29,115],"HIV (Human Immunodeficiency Virus)","2026-05-04",{"date":96,"type":35},{"date":119,"type":35},"2026-04-23",{"date":121,"type":22},"2027-11",{"name":123,"class":42},"Naga P. Chalasani",10,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":43},"100607851","phase-2-investigation-of-the-efficacy-of-a-probiotic-mixture-in-moderate-metabolic-dysfunction-associated-steatotic-liver-disease-masld-a-mechanistic-trial-100607851","NCT07193927","Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial","Investigation of the Efficacy of a Probiotic Mixture in Subjects With Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial","Inclusion Criteria:\n\n* Patients aged from 18 to 75 years old\n* BMI 25 - 42kg\u002Fm2\n* Diagnosed with MASLD and CAP value \\> 268 dB\u002Fm evaluated by FibroScan®\n* High ALT levels (\\>30 U\u002FL in males and \\>19 U\u002FL in females)\n* Having at least three of the following features compatible with metabolic syndrome:\n\n  i. Waist circumference ≥ 102 cm in males and ≥ 88 cm in females. ii. Fasting serum glucose (≥ 5.6 mmol\u002FL or 100 mg\u002Fdl). iii. Glycated haemoglobin (HbA1c ≥ 5.7%\u002F 39 mmol\u002FL). iv. Diagnosed or treated for type 2 diabetes. v. High blood pressure (≥ 130\u002F85 mmHg). vi. High plasma triglycerides (≥ 1.70 mmol\u002FL or 150 mg\u002Fdl). vii. Lower plasma of High-Density Lipoprotein (HDL cholesterol) (≤ 1.0 mmol\u002FL or 40 mg\u002Fdl for males and ≤ 1.3 mmol\u002FL or 50 mg\u002Fdl for females).\n* Stable weight in the last 3 months (less than ± 4% weight variation).\n* Stable medication or intake of food supplements for a medical condition that can affect study outcomes according to the Investigator's judgement in the last three months prior to study entry (bile salt sequestrants are not permitted).\n* Not planning to change their dietary and lifestyle habits during the study.\n* Willing and able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Fibrosis scores equal or higher than F2 (≥ 8.0 kPa).\n* History of acute or chronic hepatitis A, B or C, autoimmune hepatitis, drug-induced liver diseases, severe liver diseases.\n* Prior or pending liver transplantation.\n\nPatients with at least one of the following concurrent conditions:\n\ni. Type I diabetes ii. Uncontrolled type II diabetes (HbA1c \\>8%) iii. Hypertriglyceridemia \\> 350mg\u002Fdl iv. Human Immunodeficiency Virus (HIV) infection v. Diagnosis of hemochromatosis\n\n* Current use of pioglitazone, SGLT-2 inhibitors, or approved drugs for MASLD or steatohepatitis within 8 weeks.\n* Current use of bile salt sequestrants within 8 weeks.\n* Significant gastrointestinal disease, such as inframmatory bowel disease (IBD, short bowel syndrome, chronic or recurrent diarrhoea, coeliac condition.\n* Pancreatic failure, biliary dysfunction (including cholecystectomy and blood bilirubin abnormalities)\n* Thyroid dysfunction, as assessed by the investigator (clinical criteria)\n* History of:\n\n  i. Cardiovascular disease (ischemic heart disease, heart failure, cerebrovascular disease, periphreal vascular disease).\n\nii. Cancer or immunosuppression. iii. Gastrointestinal surgery in the previous year (with the exception of appendicitis).\n\n* Patients with a history of chronic alcohol or drug abuse: \\> 14 units\u002Fweek for females and \\> 21 units\u002Fweek for male\n* Chronic and heavy smoking (\\>20 cigarettes a day)\n* Regular intake (\\> 3 days\u002Fweek) of other probiotics (including food complements or diary foods with other probiotic strains, e.g. Activia®, Actimel® or similar).\n* Intake of nutraceuticals with an effect on hepatic function such as \\> 500 mg\u002Fday omega-3 fatty acids, high-dose vitamin E supplements or milk thistle (sylibum marianum) extract ot their active ingredients (silymarin, silybin) regularly (\\> 7 days) in the 15 days before study entry.\n* Current use of systemic corticosteroids, androgens, clopidogrel, digoxin, acenocoumarol, warfarin, phenytoin, topiramate, lithium, tricyclic antidepressants, MAOIs or second-generation antipsychotics, amiodarone, tamixofen and\u002For diltiazem.\n* History of use (\\> 3 days) of oral or parenteral antibiotics one month before the study initiation.\n* Chronic use of laxatives.\n* Debilitating illnesses (advanced liver or kidney disease, severe depression, psychotic symptoms, neurological diseases).\n* Current pregnancy (positive urine test) or planning to become pregnant during the study.\n* Breastfeeding at the time of eligibility assessment.\n* Patients who have participated in a clinical trial in the six-month period before the study.","75 Years",{"count":85,"type":22},[112],"The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nThe main questions it aims to answer are:\n\nCan the probiotics improve liver fat and stiffness as measured by non-invasive imaging (FibroScan® CAP and FAST scores)? Does the probiotic affect other health markers like cholesterol, blood sugar, inflammation, and gut bacteria?\n\nResearchers will compare people taking the probiotic to those taking a placebo (a capsule with no active ingredients) to see if the probiotic has beneficial effects.\n\nParticipants will:\n\nBe randomly assigned to take either the probiotic or placebo daily for 6 months.\n\nAttend 3 study visits (at the start, 3 months, and 6 months). Provide blood and stool samples. Undergo liver scans (FibroScan®). Complete a health and nutrition questionnaire.\n\nThis study includes adults aged 18-65 with moderate MASLD and certain metabolic health conditions. Participants must not be pregnant, breastfeeding, or taking certain medications or supplements that could interfere with the study.",[29,137,138],"Fatty Liver Disease, Nonalcoholic","Overweight (BMI > 25)","2026-04-29",{"date":141,"type":35},"2026-04-30",{"date":143,"type":35},"2026-03-20",{"date":145,"type":22},"2027-06-01",{"name":147,"class":148},"AB Biotics, SA","INDUSTRY",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":43},"100598579","effects-of-normobaric-hypoxic-training-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100598579","NCT07073326","Effects of Normobaric Hypoxic Training in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Effects of Normobaric Hypoxia Aerobic Training in People With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","HYPOMASLD","Inclusion Criteria:\n\n* Being diagnosed with MASLD from at the least 3 years\n* BMI \\> 26 kg\u002Fm2\n* Being sedentary\n\nExclusion Criteria:\n\n* Cardiovascular, respiratory, renal complications\n* Hypertension\n* COPD\n* Previous history of acute mountain sickness or altitude-associated symptoms\n* Females only: pregnancy or breastfeeding","50 Years",{"count":159,"type":22},20,[25],"Altitude training has been suggested to be of potential support to improve some chronic clinical conditions, especially metabolic conditions. Normobaric hypoxia represents a promising system to simulate altitude training, and its efficacy and safety have been suggested in different conditions, including diabetes, obesity and hypertension. Metabolic dysfunction-associated steatotic liver disease (MASLD) can characterized by metabolic alterations (including altered body composition, lipid and glycemic profile, etc.), and might benefit from aerobic training performed in simulated altitude training (i.e., normobaric hypoxia). Mild altitude training will be proposed (equal to about 2'500 m, 15% FiO2) and compared to a sham normobaric normoxia condition, during an 8-week 3 or 2 times per week 1-h aerobic training (walking) at 60-65% of maximum heart rate (HRmax). Cardiorespiratory fitness, body composition, and metabolic profile will be investigated.",[29,163],"Normobaric Hypoxia",[165,166,167,168,169,170],"Hypoxia","Altitude","Exercise","Liver","Metabolism","Fat","2026-04-27",{"date":116,"type":35},{"date":174,"type":35},"2025-09-01",{"date":176,"type":22},"2026-07",{"name":178,"class":42},"University of Trieste",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":188,"studyType":189,"phases":4,"briefSummary":190,"conditions":191,"keywords":196,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100629537","prevalence-and-risk-factors-of-metabolic-associated-hepatic-steatosis-in-individuals-living-with-type-1-diabetes-100629537","NCT07475962","Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes","STEA-DT1","Inclusion Criteria:\n\n* Individuals ≥ 18 years of age.\n* A clinical diagnosis of type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) for at least one year, as per the investigators' clinical judgment (confirmatory C-peptide and antibodies will not be required).\n\nExclusion Criteria:\n\n* Alcohol consumption exceeding 20g per day in women or 30g per day in men.\n* Known chronic liver disease (including viral, drug-induced, Wilson disease, deficit in alpha-1-antirypsin, hemochromatosis, autoimmune hepatitis, etc.).\n* Evidence of cirrhosis based on a result of liver biopsy, or history of portal hypertension presented by ascites, hepatic encephalopathy or varices.\n* History of use of medications known to induce liver steatosis, including corticosteroids, high-dose estrogens, tamoxifen, methotrexate, amiodarone, or tetracycline.\n* Ongoing pregnancy.\n* Life expectancy of less than 5 years, as per investigators' clinical judgment.",{"count":187,"type":22},100,"3 Days","OBSERVATIONAL","The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older living with type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) in Quebec.\n\nThe main questions it aims to answer are:\n\n1. What is the prevalence and severity of liver steatosis and fibrosis among people living with type 1 diabetes in Québec?\n2. Are there patients with type 1 diabetes who have advanced, undiagnosed stages of liver disease that require management but are missed by current standard care practices?\n\nResearchers will compare three participant subgroups based on adiposity (a control group without increased adiposity, an overweight group with increased adiposity, and an obesity group with increased adiposity) to see if the prevalence and severity of hepatic steatosis and fibrosis are highest in the obesity group and lowest in the control group. They will also explore if variables and potential risk factors associated with liver disease differ across these subgroups.\n\nParticipants will attend a single study visit where they will be asked to:\n\n* Provide clinical data through laboratory analyses.\n* Undergo specific clinical procedures.\n* Complete validated questionnaires.",[192,193,29,194,195],"Type 1 Diabetes","Liver Steatoses","Liver Fibrosis","Latent Autoimmune Diabetes in Adult (LADA)",[61,197,198,199,200,201],"Liver steatosis","Liver fibrosis","LADA","Body composition","Type 1 diabetes","2026-03-19",{"date":204,"type":35},"2026-03-23",{"date":206,"type":22},"2026-04-01",{"date":208,"type":22},"2027-05-30",{"name":210,"class":42},"Institut de Recherches Cliniques de Montreal",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":52,"sex":17,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":223,"conditions":224,"keywords":236,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":43},"100629594","expanded-studies-on-the-scapis-stockholm-reexamination-cohort-100629594","NCT07476703","Expanded Studies on the SCAPIS Stockholm Reexamination Cohort","Expanded Studies of Risk Factors for Pulmonary-, Liver-, and Cardiovascular Disease in the SCAPIS 2 Stockholm Reexamination","SCAPIS-ReEx","Inclusion Criteria: Subjects already included in the main \u002F general SCAPIS reexamination study in Stockholm.\n\nExclusion Criteria: Inability to provide consent.","56 Years","74 Years",{"count":222,"type":22},1400,"The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. The study is a collaborative effort among six university hospitals across Sweden. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet.\n\nSCAPIS 2 includes a core set of examinations involving blood sampling, questionnaires, and imaging. In addition to these, complementary local investigations are conducted to enable more detailed research questions. This protocol describes the additional studies conducted in the Stockholm cohort. All complementary assessments aim to identify risk factors for current and future lung, liver, and cardiovascular diseases.:\n\nEXTENDED SAMPLING: Saliva and Blood Samples with Blood Cell Isolation. EXTENDED QUESTIONNAIRES: Dyspnea, Sleep, Respiratory Infections, and Dental Health.\n\nEXTENDED IMAGING AND PHYSIOLOGICAL MEASUREMENTS Cardiac Ultrasound and Abdominal Aortic Measurements. Liver Elastography. Vascular Stiffness by cuff-based pulse wave analysis and Photoplethysmography (PPG). Valvular and Vascular Calcification by CT imaging.",[225,226,227,228,229,230,231,232,233,234,29,235],"Coronary Artery Disease","Arterial Stiffness, Blood Pressure","AORTIC VALVE DISEASES","Mitral Valve Stenosis and\u002For Insufficiency","Heart Failure","Pulmonary Disease, Chronic Obstructive (COPD)","Steatohepatitis","Inflammation Biomarkers","Lipid Profile","Oral Microbiota","Metabolic Associated-dysfunction Steatohepatitis (MASH)",[237,238,61,239,240,241,242,243],"coronary artery disease","arterial stiffness","COPD","inflammation","dyslipidemia","aortic aneurysm","oral microbiota","2026-03-12",{"date":246,"type":35},"2026-03-17",{"date":248,"type":35},"2024-04-08",{"date":250,"type":22},"2026-08-30",{"name":252,"class":42},"Danderyd Hospital",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":261,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":43},"100628889","exercise-for-an-aging-liver-exaliver-100628889","NCT07467512","Exercise for an Aging Liver (EXALIVER)","Evaluation of the Impact of Physical Exercise on Metabolic Dysfunction-associated Steatotic Liver Disease in the Elderly","EXALIVER","Inclusion Criteria:\n\n* Middle-aged adults (40 to 60 years old) and older adults (aged 70 years or older)\n* People diagnosed with Metabolic Disfunction-Associated Steatotic Liver Disease (MASLD); defined as the presence of hepatic steatosis (≥5% fat content) in conjunction with at least one cardiometabolic risk factor (overweight or obesity, dysglycaemia or Type II diabetes, elevated plasma triglycerides, reduced HDL-cholesterol or high blood preassure) with no other discernable cause.\n* People diagnosed with at-risk Metabolic Disfunction-Associated SteatoHepatitis (MASH) according to the following criteria: I) a positive liver biopsy (NAS score ≥ 4 points (with at least one point in each of the components of the score: steatosis, lobular inflammation and ballooning, AND significant (F2) or advanced (F3) fibrosis), or II) a FAST score \\>0.65.\n\nExclusion Criteria:\n\n* Descompensated cirrhosis or end-stage liver disease.\n* Other causes of liver disease, such as alcohol abuse or drug-induced, virus-related, or hereditary disease.\n* History of a major adverse cardiovascular event, clinically significant kidney, endocrine, or neurological disease, bariatric surgery, HIV\u002FAIDS, known inflammatory and\u002For rheumatologic disease, cancer, or other medical condition in which exercise is absolute contraindicated.\n* Recent or planned major surgery, as well as anticancer therapies.\n* Participating in a weight loss, a weight-management program or a supervised exercise program (more than 30 minutes three times per week, or 45 minutes twice a week, moderate\u002Fvigorous intensity).\n* Body weight instability. Participants must have maintained the body weight registered at screening visit (tolerance: 5%) for more than 3 months.\n* Regular use of medication or compounds that may affect study outcomes based on research staff criteria.\n* Pregnancy and lactation or planned pregnancy (within the study period).\n* Frequent travel over time zones during the study period.\n* Fear of needles and claustrophobia to magnetic resonance imaging (MRI).\n* Low physical function (ie, ambulation dependency)\n* Being unable to understand and to accept the instructions or the study objectives and protocol.","40 Years",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis (MASH); comparing responses between middle-aged adults (40-60 years old) and older adults (70 years and older) of any sex, as well as between participants with low-risk MASLD and high-risk MASH. The main question it aims to answer is:\n\nCould an exercise program reduce liver fat, inflammation and fibrosis, regardless of age and disease severity?\n\nResearchers will compare 4 different groups:\n\nA) older adults with at risk MASH who will exercise B) middle-aged people with at risk MASH who will exercise C) middle-aged people with low-risk MASLD who will exercise D) middle-aged people with low-risk MASLD who will not exercise, receiving usual care.\n\nParticipants in the exercise groups will take part in a supervised 12-week exercise program that includes both strength and aerobic training, completed twice a week.\n\nAll participants, including those receiving usual care, will have health asssessments before and after the 12-week period to measure changes in liver health.",[29,266,267],"MASH - Metabolic Dysfunction-Associated Steatohepatitis","Liver Fibrosis\u002FNASH","2026-03-09",{"date":244,"type":35},{"date":271,"type":22},"2026-03",{"date":273,"type":22},"2027-10",{"name":275,"class":276},"Consorcio Centro de Investigación Biomédica en Red (CIBER)","OTHER_GOV",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":43},"100626813","spleen-stiffness-measurement-for-the-detection-of-advanced-fibrosis-100626813","NCT07440511","Spleen Stiffness Measurement for the Detection of Advanced Fibrosis","Spleen Stiffness Measurement for the Detection of Advanced Fibrosis and Prognostication in Patients With Metabolic-dysfunction Associated SteatoHepatitis","S-MASH","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of MASLD according to EASL guidelines\n* Presence of cACLD confirmed by histology (fibrosis F3-F4) or assessed non-invasively (LSM \\> 15 kPa), OR suspected cACLD based on non-invasive tests (LSM \\> 8 kPa) that leads to or has led to the indication for liver biopsy according to routine clinical practice\n* Signed informed consent for the prospective cohort\n\nExclusion Criteria:\n\n* Other etiologies of liver disease, including viral, autoimmune\u002Fcholestatic, drug-induced, alcohol-related liver disease (ALD), or use of hepatotoxic drugs (e.g. long-term oral corticosteroids, estrogen-progestin therapy, methotrexate, valproic acid)\n* Primary or secondary liver cancer\n* Previous hepatic decompensation\n* Hematological disorders\n* Portal vein thrombosis\n* Previous TIPS placement\n* Previous liver transplantation\n* Current or past extrahepatic malignancy (\\\u003C 5 years)\n* Previous bariatric surgery (\\\u003C 3 years)",{"count":286,"type":22},500,"Measurement of spleen stiffness (SSM) has shown potential as a complementary tool to liver stiffness measurement (LSM) for the assessment of portal hypertension in patients with MASLD, particularly in the setting of compensated advanced chronic liver disease (cACLD). The 100-Hz probe for SSM, developed more recently, improves the accuracy of spleen stiffness measurements by better capturing the specific characteristics of the splenic parenchyma. This method has been shown to correlate well with HVPG, the gold standard for the assessment of portal hypertension, and has demonstrated good predictive value for the detection of high-risk varices, which are indicative of advanced liver disease.\n\nThe correlation between SSM and other clinical markers, such as spleen size and platelet count, has proven to be strong, further supporting its utility in assessing disease progression. This makes SSM a promising non-invasive tool for early detection and risk stratification in MASLD, which is crucial for preventing progression to more severe stages such as cirrhosis or hepatocellular carcinoma.\n\nIn conclusion, the combined use of LSM and SSM shows great potential for improving the non-invasive diagnosis and monitoring of MASLD, providing an efficient alternative to more invasive methods such as liver biopsy and HVPG. This evidence has led to the inclusion of SSM use in clinical guidelines for the management of patients with chronic liver disease. Nevertheless, further studies are needed to confirm these findings and to refine clinical protocols, potentially allowing earlier intervention and improved management of patients with MASLD and its complications.",[29],"2026-02-23",{"date":291,"type":35},"2026-02-27",{"date":293,"type":35},"2026-01-28",{"date":295,"type":22},"2033-01",{"name":297,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":304,"maxAge":18,"enrollmentInfo":305,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":43},"100570408","quantitative-ultrasound-to-assess-steatotic-liver-disease-in-children-100570408","NCT06706856","Quantitative Ultrasound to Assess Steatotic Liver Disease in Children","Inclusion Criteria:\n\n* Age 9 to 18 years\n* Presence of risk factors for having MASLD\n* Ability and willingness of participant or legal guardian\u002Fparent to give written informed consent\n* Participant is willing to give written assent\n* Able and willing to undergo all study procedures\n\nExclusion Criteria:\n\n* Known liver disease other than MASLD\n* Pregnant or trying to become pregnant\n* Inability to undergo an MR study: weight exceeding scanner table limit, waist circumference \\> 140 cm, claustrophobie, and\u002For metal implants.","9 Years",{"count":110,"type":22},"This research study is being conducted to find out more about advanced ultrasound techniques to non-invasively evaluate liver disease in children. The investigators are developing advanced techniques for analyzing ultrasound data and images of the liver, and they will compare it to other established methods used to evaluate the liver, including liver MRI.\n\nThe investigators plan to develop and test the advanced analysis techniques using conventional full-size ultrasound machines and, if possible, small handheld devices.\n\nOur goals are:\n\n* To assess the accuracy of the advanced ultrasound analysis techniques in children\n* To implement and assess these advanced technique on small handheld ultrasound devices, if possible",[61,29],[61,309,310,311,312,313],"steatosis","quantitative ultrasound","quantitative MRI","fat fraction","PDFF","2026-01-18",{"date":316,"type":35},"2026-01-21",{"date":318,"type":35},"2024-09-23",{"date":320,"type":22},"2029-06-30",{"name":322,"class":42},"University of California, San Diego",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":43},"100615869","corazones-unidos-study-100615869","NCT07298213","Corazones Unidos Study","Pilot Test of Su Corazon Su Vida Among Mexican Origin Adults With MASLD","Inclusion Criteria:\n\n* Eligible intervention participants must (1) be Mexican-origin\u002FMexican decent, (2) be ≥ 18 years old, (3) have a confirmed MASLD diagnosis (CAP score of ≥ 248 dB\u002Fm); (4) have an adult member of their social network who might be interested in participating in the study and who lives within 25 miles of the participant's residence; (5) be able to provide informed consent; and (6) be able to speak, read, and write in English and\u002For Spanish. Eligible social support participants must (1) be ≥ 18 years old, (2) be first degree blood relative or spouse\u002Fsignificant other to the intervention participants, (3) be able to provide informed consent; and (4) be able to speak, read, and write in English and\u002For Spanish.\n\nExclusion Criteria:\n\n* Exclusion for individuals interested in the intervention component of the study will be excluded if they report (1) ongoing or recent alcohol consumption (≥21 standard drinks on average per week in men and ≥14 standard drinks on average per week in women); (2) previous diagnosis of liver cancer; (3) taking any anti-inflammatory or hepatoxic medication regularly; (4) taking medication for any form of psychiatric disorders; (5) diagnosis of depression; (6) diagnosis of autoimmune disorders; or (7) women who are pregnant or breastfeeding due to hormonal changes. Exclusion for those interested to be part of the study as social network participants will not be considered for participation if they (1) live more than 25 miles of the intervention participant's residence.",{"count":331,"type":22},45,[25],"CVD is the leading cause of death among individuals with MASLD, a risk factor for liver cancer. In Southern Arizona, CVD and cancer (including liver and gastric cancer) are among the leading causes of death for Mexican-origin adults.1 Given Mexican-origin adults' disproportionate burden of CVD-related mortality37 and higher rates of MASLD compared to other ethnic\u002Fracial groups; we urgently need to develop contextually tailored strategies for management of CVD risk factors and outcomes. Thus, the purpose of this study is to examine the acceptability and feasibility of a community health worker (CHW)-led intervention aimed to increase cardiovascular risk awareness and promote lifestyle modifications among Mexican-origin adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the Southern Arizona region. The proposed project has the potential to improve health outcomes for this vulnerable population and contribute to the ACS-CHERC's overarching goal of improving health equity for Hispanic communities and family caregivers.",[335,29],"CVD - Cardiovascular Disease","2025-12-11",{"date":338,"type":35},"2025-12-23",{"date":340,"type":35},"2025-07-18",{"date":342,"type":22},"2026-07-17",{"name":344,"class":42},"University of Arizona",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":132,"enrollmentInfo":353,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":43},"100613746","development-of-a-quantifiable-ultrasound-biomarker-for-hepatic-steatosis-100613746","NCT07270601","Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis","Development and Diagnostic Evaluation of a Novel Quantifiable Ultrasound Based Multi-parametric Biomarker for Hepatic Steatosis in Patients With Suspected MASLD ( LYNX )","LYNX","Inclusion Criteria:\n\nDiseased subject:\n\n* Adult patients (age 18 - 75 years)\n* Consent to participate in the study\n* Diagnosed or suspected MASLD from the hepatology clinic, OR\n* High-risk population meeting the adult cardiometabolic criteria (defined as the presence of at least one of the following: diabetes, obesity (BMI ≥ 25 kg\u002Fm2), hypercholesterolemia, and hypertension)\n\nHealthy volunteer:\n\n* Adult patients (age 18 - 75 years)\n* Consent to participate in the study\n* No suspicion of MASLD by laboratory\u002Fimaging\u002Fclinical examinations\n* Absence of known pre-existing conditions (metabolic syndrome, diabetes mellitus, obesity, insulin resistance, dyslipidemia, etc.)\n\nExclusion Criteria:\n\n* Pregnancy or nursing.\n* Contraindications to MRI including, but not limited to, severe claustrophobia, pacemaker, or existing metallic\u002Fmechanical implant(s).\n* Acute illness\u002Fcognitive impairment resulting in an inability to cooperate with the MRI and ultrasound breath-holding instructions.\n* BMI \\> 35 kg\u002Fm2\n* History of excessive alcohol consumption according to the updated MASLD criteria (\\>2 drinks\u002Fday OR \\>210 grams\u002Fweek for males AND \\>1 drink\u002Fday OR \\>140 grams\u002Fweek for females) or drug use over the past 2 years.\n* Known acute or chronic hepatitis; or other etiology of liver disease.\n* Presence of known congenital hepatic anomaly.\n* Known cirrhosis\n* Known active cancer",{"count":354,"type":22},110,[25],"The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.",[29,358],"NAFLD - Non-Alcoholic Fatty Liver Disease",[61,360,361,362,363,364],"NAFLD","Ultrasound","Steatosis","Fibrosis","MRI-PDFF","2025-11-26",{"date":367,"type":35},"2025-12-08",{"date":369,"type":35},"2025-11-17",{"date":371,"type":22},"2026-12-31",{"name":373,"class":148},"ContextVision AB",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":43},"100570332","chrononutrition-chronotoxicity-intervention-in-people-with-metabolic-associated-steatotic-liver-disease-100570332","NCT06705868","Chrononutrition\u002F Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.","Time-restricted Eating in Patients With Metabolic-associated Steatotic Liver Disease . CHRONOMASLD: A Chrononutrition\u002FChronotoxicity Randomized Controlled Trial.","CHRONOMASLD","Inclusion Criteria:\n\n1. Body mass index 25 (±0,5)-45(±0,5) kg\u002Fm2\n2. Clinical diagnosis of MASLD, not excluding undiagnosed NASH or with NASH stage F0-F1\n3. Self-reported habitual eating period more than or equal to 14 h per day, BUT NOT LESS.\n4. Cyprus inhabitants of for at least 1 year\n5. Registered to the National Health System of the Republic of Cyprus (Gesy\n\nExclusion Criteria:\n\n1. Night Shift worker\n2. Fasting \\>12-h\u002Fday more than once a week or \\> once a week no food intake after 18:00\n3. Co-existing causes of chronic liver disease according to standard diagnostic testing including, but not restricted to:\n\n   1. Positive hepatitis B surface antigen\n   2. Positive hepatitis C virus RNA\n   3. Suspicion of drug-induced liver disease\n   4. Alcoholic liver disease\n   5. Autoimmune hepatitis\n   6. Wilson's disease\n   7. Hemochromatosis\n   8. Primary biliary cholangitis or primary sclerosing cholangitis\n   9. Known or suspected hepatocellular carcinoma\n4. Medications which cause liver disease or secondary hepatic steatosis (Tamoxifen, systemic corticosteroids, methotrexate, tetracycline, estrogens, valproic acid, and statin (registration is possible if statin is delivered in a consistent dosage within 12 weeks)\n5. Current or recent history (\\\u003C5 years) of significant alcohol intake (\\>30g of alcohol\u002F day or \\>210g\u002Fweek for men, \\>20g of alcohol\u002Fday or \\>140g\u002Fweek for women)\n6. Doctor diagnosed diabetes mellitus on insulin or sulfonylureas\n7. Severe medical comorbidities \\[ischemic heart disease, 3rd degree atrioventricular block, chronic obstructive pulmonary disease, severe hypertension (blood pressure \\>200\u002F120 mmHg)\\]\n8. Unstable weight (\\>5% change in the last 2 months) or participation in a weight-loss program within the past 12 weeks\n9. Sleep disorder (with a medical diagnosis) or individuals self-reporting sleep difficulties and poor sleep \\[average sleep less than 6 consecutive hours or patients who systematically experience sleep interruption for more than 2 times each night (waking up for toilet use is not to be considered sleep interruption)\\]\n10. Individuals with food allergies (or hypersensitivity to the fruits and vegetables that will be selected for the study)\n11. Systematic organic products consumers (defined as a self-reported usual consumption of more than 80% of their weekly fruits \\& vegetables being organic)\n12. Pregnant or trying to become pregnant or lactating women\n13. People not in position to communicate in Greek or English language\n14. Having metallic parts in the body.",{"count":383,"type":22},150,[25],"The goal of this clinical trial is to study the effect of a time-restricted eating (TRE) dietary pattern combined with a time of consumption restriction about the daily portions of fruits and vegetables in people diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nThe protocol of the study is an intention to treat protocol. The main research questions are:\n\n1. Does compliance in a TRE dietary scheme (positively) affect changes in body weight and body fat mass in people diagnosed with MASLD?\n2. Does an additional time restriction on the consumption of fruits and vegetables within the \"light-window\" of the day affects the metabolism of food contaminants?\n\nParticipants will be asked to:\n\n1. Adhere to a TRE dietary pattern for 3 months. TRE consists of an 8-hour eating vs 16 hours fasting within the day. First meal of the day should not occur at least an hour after wake-up time and last meal of the day should occur not later than 2 hours before bed-time.\n2. Adhere to a further time restricted consumption of a \"5-a-day\" portions of fruits and vegetables between the \"light-window hours\" between 9am to 4pm.\n3. Visit the Nutrition \\& Dietetics Clinic once every month for anthropometric measurements (on 4 time points).\n4. Collect and deliver first morning urine samples (on 7 time points).\n5. Collect and deliver saliva samples at baseline and at the end of the trial (Saliva collection should occur every 4-hours for 48-hours including fasting collection at baseline and at the end of three months)\n\n5\\) Complete a compliance and lifestyle questionnaire questionnaire via telephone interview to the research team every 2 weeks.\n\n6\\) Share photos to the research team with the use of an application on time of actual fruit and vegetables consumption, 3-4 times per week throughout the study protocol.\n\nResearchers will compare the designed intervention package of this TRE with the Standard of Care (SoC) protocol (based on the international guidelines) that is currently used in daily practice for the management of MASLD.",[61,29,360,358,387],"NAFLD (Nonalcoholic Fatty Liver Disease)",[389,390,391,392,393,394,61,395],"non alcoholic fatty liver disease (NAFLD)","chrononutrition","intermittent fasting","randomized controlled trial (RCT)","chronotoxicity","time restricted eating","Metabolic Dysfunction-Associated Steatotic Liver Disease","2025-11-18",{"date":398,"type":35},"2025-11-19",{"date":400,"type":22},"2026-01-05",{"date":402,"type":22},"2029-12-15",{"name":404,"class":42},"Cyprus University of Technology",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":23,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":426},"100609613","screening-cardiometabolic-opportunities-using-transformative-echocardiography-artificial-intelligence-scout-echo-ai-100609613","NCT07216859","Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)","SCOUT Echo-AI","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Underwent routine TTE within site defined recent timeframe and flagged as high risk for MASLD and\u002For cirrhosis by the AI model using pre specified threshold.\n* Able to provide informed consent; reachable for follow up.\n\nExclusion Criteria:\n\n* Inability to consent or communicate.\n* Enrollment in hospice or life expectancy so limited that additional evaluation would not be appropriate per clinician judgment.\n* Clinical circumstances where immediate alternative diagnostic pathways supersede study procedures (e.g., acute decompensation requiring urgent management).\n* Prior liver or kidney transplant.\n* Patient unwilling to undergo prospective testing for liver disease.",{"count":413,"type":22},2000,[25],"The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and\u002For cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs).\n\nThe main question it aims to answer is to:\n\n1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment.\n2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.",[29,417],"Cirrhosis","2025-11-13",{"date":369,"type":35},{"date":421,"type":22},"2026-01-01",{"date":423,"type":22},"2027-11-01",{"name":425,"class":42},"Kaiser Permanente",4,{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":435,"enrollmentInfo":436,"targetDuration":4,"studyType":23,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":43},"100600439","phase-2-effect-of-ketone-esters-on-liver-fat-content-and-metabolic-function-100600439","NCT07097506","Effect of Ketone Esters on Liver Fat Content and Metabolic Function","Effect of Ketone Esters on Liver Fat and Metabolic Function in Adolescents With Obesity and MASLD","JV","Inclusion Criteria:\n\n* Age: ≥18 and ≤25 years;\n* BMI 25.0 - 44.9 kg\u002Fm2;\n* Intrahepatic triglyceride content \\>5% assessed by using magnetic resonance imaging-proton density fat fraction (MRI-PDFF).\n\nExclusion Criteria:\n\n* HbA1C ≥6.5%;\n* taking dietary supplements or medications known to affect our study outcomes including corticosteroids and other drugs associated with steatosis (metformin use will be allowable if participants have taken a stable dose for at least 3 months without any gastrointestinal-related symptoms);\n* active eating disorder, any anaphylactic food allergy and\u002For consuming a very-low-carbohydrate (\\\u003C50 g\u002Fday) diet;\n* Fibroscan controlled attenuation parameter (CAP) score \\\u003C240 dB\u002Fm assessed within last 2 months before entering the study;\n* recent (\\\u003C2 months) history of moderate-severe nausea, vomiting, diarrhea, or other significant gastrointestinal symptoms;\n* consume tobacco products, excessive alcohol (females: \\>14 drinks\u002Fweek; males: \\>21 drinks\u002Fweek), or illegal drugs determined by medical history;\n* evidence of significant active organ system dysfunction, liver disease other than MASLD (e.g., Wilson disease, viral hepatitis, inborn errors of metabolism, or alpha-1 antitrypsin deficiency) or cirrhosis as a results of any condition or disease;\n* have had bariatric surgery or plan to have endoscopic or bariatric surgery therapy for obesity;\n* have undergone organ transplantation;\n* have HIV and any other type of congenital or acquired lipodystrophy;\n* unwilling or unable to provide informed consent;\n* major psychiatric illness;\n* metal implants that are not MRI-compatible;\n* pregnancy, as determined by a urine HCG screening test assessed performed at all screening, baseline testing, and follow-up visits. In addition, male and female participants of reproductive and childbearing age who wish to enroll will be required to agree to use contraception throughout the study period, and for 30 days after the last dose of C8 ketone di-ester;\n* female participants who are currently lactating;\n* Structured exercise: ≥75 min\u002Fwk of vigorous exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥200 min\u002Fwk of low intensity physical activity (e.g., brisk walking);\n* Unstable weight (\\>3% change during the last 2 months before entering the study);\n* Anemia (hemoglobin \\\u003C10.5 g\u002FdL in females and \\\u003C11.0 g\u002FdL in males);\n* Unable or unwilling to follow the study protocol or who, for any reason, is considered an inappropriate candidate for the study by the research team.","25 Years",{"count":21,"type":22},[112],"The goal of this clinical trial is to determine whether ingestion of a ketone ester drink helps improve liver health and blood glucose control. Ketones are a type of energy source made by the body during times of weight loss, low carbohydrate intake and starvation.\n\nPeople enrolled in this study will be randomly assigned (by chance, like the flip of a coin) to one of two groups:\n\nGroup 1: Ketone ester drink consumed daily for 6 weeks. Group 2: Placebo drink consumed daily for 6 weeks.",[29,440,441],"Obesity","Overweight (BMI > 25)","2025-11-10",{"date":444,"type":35},"2025-11-12",{"date":446,"type":35},"2025-09-26",{"date":448,"type":22},"2027-12-31",{"name":450,"class":42},"Washington University School of Medicine",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":11,"sex":17,"minAge":457,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":43},"100599980","food-insecurity-and-masld-a-fruit-and-vegetable-intervention-study-100599980","NCT07091539","Food Insecurity and MASLD: A Fruit and Vegetable Intervention Study","Inclusion Criteria:\n\n* The study population for all study aims consists of children and adolescents receiving care at the liver and WATCH clinics.\n\nInclusion criteria include:\n\n* family living in California;\n* a parent\u002Fguardian who speaks Spanish or English,\n* child is between the ages of 6 to \\\u003C18 years;\n* child has elevated BMI greater than or equal to 85% for age and sex\n* child has ALT value greater than 26 for boys and 22 for girls on two occasions within the last year; OR one elevated ALT value and imaging confirming steatosis\n* family does not intend to move out of California for the next year;\n* family is not already receiving EatSF Fruit and Vegetable Vouchers;\n* family is not participating in any other dietary education programs besides that offered by the liver\u002F WATCH clinics\n\nExclusion Criteria:\n\n* child has an underlying condition or medication causing their weight gain (i.e., hypothyroidism, Prader-Willi syndrome, antipsychotic medications) or a known liver condition other than MASLD\u002FMASH causing their elevated liver numbers;\n* child is on a weight loss medication (including: Qsymia or GLP-1 receptor agonists),\n* both of which are assessed as part of routine clinical care.","6 Years","17 Years",{"count":460,"type":22},48,[25],"This proposal addresses a critical gap in the understanding of the impact of household food insecurity (FI) on pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) severity. Evidence from adult studies links household FI to MASLD and liver fibrosis, and prior research of the PI has shown that exposure to household FI in early childhood was associated with a nearly fourfold increased odds of pediatric MASLD in middle childhood. Possible mechanisms linking household FI to pediatric MASLD include lower intake of fruits and vegetables, higher intake of caloric dense nutrient-poor foods (e.g., sugar-sweetened beverages), and less diversity of foods. Given consensus recommendations for the management of MASLD focus on lifestyle modification, i.e., diet and exercise to achieve weight loss, this proposal seeks to assess whether a clinic-based fruit\u002Fvegetable voucher intervention program (EatSF) could potentially improve clinical outcomes for children\u002Fadolescents with MASLD and household FI. Study participants include children\u002Fadolescents with household FI and MASLD who are receiving care at UCSF's liver clinic and Weight Management for Teen and Child Health (WATCH) Clinic, a pediatric subspecialty clinic. The study seeks to identify barriers and facilitators to fruit\u002Fvegetable voucher redemption, and assess changes in dietary intake, MASLD severity, and other cardiometabolic health factors in children participating in the pilot intervention. Study findings will form the basis of an R01 application to conduct a fully powered randomized controlled trial of the intervention.",[29,464],"Food Insecurity Among Children",[61,466,467],"Food insecurity","pediatrics","2025-08-29",{"date":470,"type":35},"2025-09-02",{"date":472,"type":35},"2025-07-30",{"date":474,"type":22},"2027-08",{"name":476,"class":42},"University of California, San Francisco",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":17,"minAge":457,"maxAge":458,"enrollmentInfo":484,"targetDuration":486,"studyType":189,"phases":4,"briefSummary":487,"conditions":488,"keywords":490,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":43},"100599868","pediatric-metabolic-dysfunction-associated-steatotic-liver-disease-and-food-insecurity-100599868","NCT07090083","Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity","Pediatric MASLD and Food Insecurity","Inclusion Criteria:\n\n* Children and adolescents receiving care in the liver and WATCH clinics.\n* Family living in California.\n* Parent\u002Fguardian speaks Spanish or English.\n* Child is between the ages of 6 to \\\u003C17 years.\n* Elevated ALT on at least 2 occasions within the past year:\n\n  * ALT \\> 22 units\u002FL for females.\n  * ALT \\> 26 units\u002FL for males.\n* BMI for age\u002Fsex ≥ 85%.\n* Alternatively, child has one elevated ALT within the past year and confirmed steatosis on imaging.\n* Family does not intend to move out of California within the next year.\n* Family is not already receiving EatSF SF Fruit and Vegetable Vouchers.\n* Family is not participating in any other dietary education programs besides those offered by the WATCH or liver clinics.\n\nExclusion Criteria:\n\n* Child has an underlying condition or medication causing their weight gain (e.g., hypothyroidism, Prader-Willi syndrome, antipsychotic medications).\n* Child is on, or expected to go on, or starts on a weight loss medication (e.g., Qsymia or GLP-1 receptor agonists).\n* Child has another known cause of liver disease (not including MASLD or MASH), such as:\n\n  * Autoimmune hepatitis.\n  * Wilson's disease.\n  * Hepatitis A, B, or C.\n  * Acute infection.\n  * Genetic condition causing inflammation in the liver.",{"count":485,"type":22},160,"30 Days","This proposal addresses a critical gap in our understanding of the impact of household food insecurity (FI) on pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) severity. There is evidence that children in families that do not have the ability to provide consistently healthy and high-quality foods, such as fruits and vegetables, have worse diet quality that children in households that are food secure. Additionally, evidence from adult studies link household FI to MASLD and liver fibrosis, and prior research of the PI has shown that exposure to household FI in early childhood was associated with a nearly 4 times increased odds of pediatric MASLD in middle childhood. Possible mechanisms linking household FI to pediatric MASLD include lower intake of fruits and vegetables, higher intake of caloric dense nutrient poor foods (e.g., sugar sweetened beverages), and less diversity of foods. Given consensus recommendations for the management of MASLD focus on lifestyle modification, i.e., diet and exercise to achieve weight loss, this proposal seeks to explore the association of household FI and pediatric MASLD disease severity and whether those effects are mediated by dietary intake. Study participants include children\u002Fadolescents with MASLD who are receiving care at UCSF's liver clinic and Weight Management for Teen and Child Health (WATCH) Clinic, a pediatric subspecialty clinic.",[29,489],"Food Insecurity",[61,491,492],"food insecurity","pediatric",{"date":470,"type":35},{"date":472,"type":35},{"date":496,"type":22},"2026-12-30",{"name":476,"class":42},{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":509,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":43},"100601779","study-on-the-function-of-taiwan-green-propolis-in-reducing-blood-lipids-and-body-fat-in-sub-healthy-groups-masld-100601779","NCT07114926","Study on the Function of Taiwan Green Propolis in Reducing Blood Lipids and Body Fat in Sub-healthy Groups: MASLD","TGP","Inclusion Criteria:\n\nAged 18 to 80 years.\n\nMeet any of the following dyslipidemia indicators:\n\nTotal cholesterol (TC) \\> 200 mg\u002FdL\n\nTriglycerides (TG) \\> 200 mg\u002FdL\n\nLDL cholesterol \\> 130 mg\u002FdL\n\nOverweight or obese (BMI ≥ 27) with abnormal waist circumference:\n\nMale \\> 90 cm\n\nFemale \\> 80 cm\n\nNot currently receiving any lipid-lowering medication treatment. MASLD\n\nExclusion Criteria:\n\n* Allergic to honey, propolis, various pollens, or alcohol.\n\nIndividuals with psychiatric disorders or cognitive impairments.\n\nPregnant or breastfeeding women.\n\nIndividuals with significant endocrine disorders or major diseases of the heart, liver, kidneys, or other organs.\n\nIndividuals with swallowing difficulties.\n\nIndividuals with dementia, impaired consciousness, or other cognitive disorders preventing informed consent.\n\nIndividuals already receiving formal lipid-lowering drug therapy.\n\nIndividuals with comorbid diabetes, chronic kidney disease, or isolated LDL \\> 190 mg\u002FdL.",{"count":85,"type":22},[25],"This study investigates the effectiveness of Taiwanese green propolis in reducing blood lipids and body fat in sub-healthy individuals. The study design follows a parallel, double-blind, randomized assignment approach, dividing participants into an experimental group (propolis) and a control group (placebo). Researchers explained the study plan to participants, and after obtaining signed informed consent, participants were randomly assigned using a web-based program that generated random serial numbers. The randomization was stratified by gender (male-to-female ratio of 1:1) and physiological age groups (maturity, middle age, menopause, post-menopause, and old age). Serial numbers and group assignments were sequentially encoded and placed in opaque, consecutively numbered envelopes. After obtaining consent, researchers opened the sealed envelopes in order and assigned participants to either the experimental group (propolis) or the control group (placebo), with 30 participants in each group.\n\nThe experimental group received Taiwanese green propolis (which can be stored at room temperature) in capsule form, containing 500 mg\u002Fml of propolis extract per capsule. Participants took two capsules before breakfast and two before dinner, totaling four capsules per day for 12 weeks. The control group received a placebo with the same dosage and administration method. All participants were instructed not to deliberately change their daily diet or exercise routines during the study. To assess adherence, participants recorded their daily propolis capsule intake. Additionally, the Health Belief Model questionnaire and the EQ-5D-5L quality of life questionnaire were used to evaluate whether the intervention with propolis, along with dietary and exercise education, contributed to increased awareness of health behaviors and improvements in quality of life.\n\nThe primary outcomes of the study include changes in blood lipids, body fat, blood glucose levels, liver fat, and liver fibrosis. The secondary outcomes focus on the correlation between health behavior awareness and quality of life.\n\nKeywords: Taiwanese green propolis, sub-health, blood lipids, body fat, Health Belief Model, quality of life.",[29],[510,511,512,513,514,515],"Taiwanese green propolis","MASLD-Metabolic Dysfunction-Associated Steatotic Liver Disease","blood lipids","body fat","Health Belief Model","quality of life","2025-08-06",{"date":518,"type":35},"2025-08-11",{"date":520,"type":22},"2025-08-30",{"date":522,"type":22},"2028-09-30",{"name":524,"class":42},"Kuo,HSIN-YU",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":534,"briefSummary":535,"conditions":536,"keywords":541,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":557},"100600119","the-impact-of-pectin-supplementation-on-systematic-inflammation-pathway-gut-microbiome-and-metabolic-health-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100600119","NCT07093346","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomised, Placebo-Controlled, Dietary Intervention Study","PEC-MASLD","Inclusion Criteria:\n\nInclusion criteria for the main study:\n\n* Patients with clinical diagnosis of MASLD (formerly termed non-alcoholic fatty liver disease (NAFLD)), having assessment suggesting that liver fat \\> 5% (e.g. histological evidence or\u002F and Transient Elastography using Controlled Attenuation Parameter (CAP)- FibroScan™ in the past month and\u002For liver imaging (such as ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI)).\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years who have a body mass index (BMI) between 18.5 and 39.9 kg\u002Fm2 and stable weight (weight gain or loss ≤ 3kg) for the past 3 months.\n* For diabetic participants: controlled blood glucose levels Haemoglobin A1C (HbA1c) \\\u003C7.0% (\\\u003C53 mmol\u002Fmol) \\[1\\].\n* Able to undergo CAP-FibroScan™.\n\nInclusion criteria for healthy participants who will have MRI scans:\n\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years.\n* participants with CAP\\\u003C250 kpa\\\u003C8kP by a FibroScan™ within the past 6 months.\n\nExclusion Criteria:\n\nExclusion criteria for the main study:\n\n* Have allergy toward soya, milk or chocolate.\n* Have allergy toward pectin.\n* Participants on vegan diet.\n* Have eating disorders or difficulties or gastrointestinal conditions e.g. malabsorptive conditions such as coeliac, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) or gastroparesis.\n* Have chronic malnutrition condition.\n* History of major surgery which potentially limits participation or completion of the study.\n* History of previous intestinal surgery known to affect food intake or digestive function, including bariatric surgery.\n* Use of antibiotics, antifungal medications, probiotics or prebiotics 90 days before the start of the study.\n* Are taking the following medications: immunosuppressants, amiodarone and\u002For perhexiline.\n* Are currently following or anticipated to commence a specialised commercially available weight loss diet and\u002For program or concomitant use of any weight loss medication or herbal weight loss products.\n* History of side effects towards probiotics or prebiotics.\n* History or current psychiatric illness.\n* History or current neurological condition (e.g. epilepsy).\n* Participants with other liver abnormalities.\n* Evidence of monogenic metabolism diseases such as Lysosomal acid lipase deficiency (LALD), Wilson disease, Hypobetalipoproteinemia, or inborn errors of metabolism.\n* Have had a weight change exceeding 3 kg within 3 months.\n* Uncontrolled diabetes, active malignancy, or chronic infections.\n* Having symptoms of active infection.\n* Excessive alcohol intake defined as self-reported intakes greater than 21 units per week in men, and 14 units per week in women.\n* Participants who are pregnant, breast feeding or actively planning pregnancy will be excluded from the study.\n* Participation in any other trial in the last 3 months.\n\nExclusion criteria for healthy volunteers MRI scans and patients optional MRI scans:\n\n* Contraindications for MRI scanning: having pacemakers, defibrillators, neurostimulators, prohibited medical implants, and foreign bodies (e.g. bullets, shrapnel, metal slivers), history of metallic foreign body in eye(s) and penetrating eye injury that could present a risk during an MRI scan.\n* Difficulty breathing or inability to lie flat, as well as conditions that could worsen under stress (such as anxiety or panic disorders, claustrophobia, uncontrolled hypertension, or seizure disorders) severe enough to prevent undergoing an MRI.",{"count":331,"type":22},[25],"The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is:\n\n-How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD?\n\nResearchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota.\n\nParticipants will:\n\n* Take a daily supplement for 6 weeks: either 15g of LM-pectin with 10g of cocoa powder (intervention), or 10g of placebo with 10g of cocoa powder (control)\n* Provide stool and fasting blood samples before and after the intervention\n* Undergo anthropometric measurements (weight, height, waist\u002Fhip ratio, and blood pressure)\n* Complete a case report form (CRF) including demographics and health\u002Fmedical history\n* Undergo a FibroScan™ to assess liver health\n* (Optional) Participate in MRI scans to evaluate gut permeability",[537,538,29,61,360,395,387,539,358,540],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Fatty Liver Disease (NAFLD)","NAFLD (Non-alcoholic Fatty Liver Disease)","NAFLD - Nonalcoholic Fatty Liver Disease",[542,543,61,360,537,544,545,546,547,548,395],"LM pectin","pectin","Systemic Inflammatory Response","Dietary Fiber","Dietary Fibre","Diet","gut microbiota","2025-07-22",{"date":472,"type":35},{"date":552,"type":35},"2025-06-10",{"date":554,"type":22},"2027-03-31",{"name":556,"class":42},"University of Nottingham",3,{"id":559,"slug":560,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":61,"eligibilityCriteria":564,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":565,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":566,"conditions":567,"keywords":571,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":43},"100429529","development-of-a-non-invasive-screening-tool-to-predict-metabolic-dysfunction-associated-steatotic-liver-disease-100429529","NCT04873258","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease","Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis","Inclusion Criteria:\n\n1. Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent.\n2. Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.\n3. An understanding, ability and willingness to fully comply with project procedures and restrictions.\n\nFor PART B only:\n\n1\\. With a known history of MASLD as evidenced either of:\n\n1. GP diagnosis on HCF\n2. Documented Fibroscan or liver US demonstrating MASLD\n\nExclusion Criteria:\n\n1. Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)\n2. Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)\n3. Alcohol consumption \\>30 units per week\n4. An Implanted cardiac devices",{"count":413,"type":22},"A generic screening study to establish structural and\u002For functional baselines of specific organs.",[568,569,61,29,570],"Healthy","Fatty Liver","Obesity and Obesity-related Medical Conditions",[572,61],"Fatty liver",{"date":574,"type":35},"2025-07-23",{"date":576,"type":35},"2019-09-27",{"date":448,"type":22},{"name":579,"class":148},"Richmond Research Institute",{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":588,"enrollmentInfo":589,"targetDuration":590,"studyType":189,"phases":4,"briefSummary":591,"conditions":592,"keywords":595,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":615,"locationsCount":43},"100577384","clinical-correlation-evaluation-of-the-liverfast-test-for-diagnosing-important-liver-lesions-of-fibrosis-and-steatosis-against-magnetic-resonance-elastography-mre-for-liver-fibrosis-and-mr-based-assessment-of-steatosis-in-adult-us-population-100577384","NCT06797596","Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.","Clinical Correlation Evaluation of the LIVERFAStTM Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against MR-based Liver Assessment, Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.","LFMRECT","Inclusion Criteria:\n\n* SLD with MASLD or MetALD Adult patients with:\n\n  * available historical report of MRE and LIVERFASt test\n  * at least fibrosis scoring available (steatosis and necro-inflammation imaging reports are requested equally when available).\n* Other imaging modality reports ie. MRI, ARFI, ct1, SWE and Fibroscan can be included when available\n\nExclusion Criteria:\n\n* Participants identified as having risk factors for false positive\u002Fnegative results for Liverfast (severe intravascular hemolysis-if condition is known-, acute hepatitis or severe cytolysis with ≥ 600 ALT values)\n* Other comorbidities not compatible with the diagnosis of MASLD or MetALD","90 Years",{"count":187,"type":22},"2 Days","This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE) and MRct1 fibrosis classification (historical records) and to assess LIVERFASt performance for MR steatosis assessment in an United States adult miscellaneous population with available (historical) MR intracellular fat fraction assessment (ICFF) from a single tertiary US clinic.",[593,29,594],"Liver Fibrosis Due to NASH","Alcohol Liver Disease",[596,597,598,599,600,601,602,603,604,605,606,607,608],"LIVERFASt","LIVERFASt Test","Noninvasive Test for the Liver","LIVERFASt for MASLD","LIVERFASt for MASH","Fibronostics","Liverfast fibrosis test","Liverfast steatosis test","Liverfast for MASLD and MASH","Liverfast for liver fibrosis","Liverfast plus MRE","Liverfast and MRE","Liverfast and other imaging tools","2025-03-10",{"date":611,"type":35},"2025-03-13",{"date":613,"type":22},"2025-05",{"date":520,"type":22},{"name":616,"class":42},"Fibronostics USA, Inc",{"id":618,"slug":619,"hasResults":11,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":624,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":43},"100545760","cardiac-dysfunction-in-patients-with-fatty-liver-disease-100545760","NCT06386094","Cardiac Dysfunction in Patients with Fatty Liver Disease","Cirrhotic Cardiomyopathy and Cardiac Dysfunction in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease","Inclusion Criteria:\n\n* Age range of 18-65 years\n* metabolic dysfunction associated steatotic liver disease as diagnosed either by histology or clinical, laboratory, non invasive tests, USG findings and vibration controlled transient elastography (VCTE).\n\nExclusion Criteria:\n\n* Age \\>65 years\n* Chronic renal disease\n* Pregnancy and peripartum cardiomyopathy\n* Hypertension\n* Valvular heart disease\n* Sick sinus syndrome\u002F Pacemaker\n* Cardiac rhythm disorder\n* Hypothyroidism\n* Hyperthyroidism\n* Portal vein thrombosis\n* Transjugular intrahepatic porto systemic shunt (TIPS) insertion\n* Hepatocellular carcinoma\n* Anemia Hb \\\u003C 8gm\u002Fdl in females, and \\\u003C 9 gm\u002Fdl in males at the time of assessment",{"count":383,"type":22},"Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and\u002For altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E\u002Fe' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.",[360,627,569,29],"Cardiac Disease",[61,629,630,225],"Cirrhotic Cardiomyopathy","Heart failure in Cirrhosis","2025-01-27",{"date":633,"type":35},"2025-01-29",{"date":635,"type":35},"2023-07-15",{"date":637,"type":22},"2027-11-15",{"name":639,"class":42},"Post Graduate Institute of Medical Education and Research, Chandigarh"]